White Pine Allergy Shots: Test Before You Treat the Wrong Allergen
White pine (Pinus strobus) is responsible for the famous yellow pollen rain of the Northeast and Great Lakes each May, yet Bucholtz 1985 found only 3.2% of pollen-sensitive patients test positive to Pinus — most are actually reacting to concurrent oak, birch, or grass. Testing before starting SCIT is essential because pine immunotherapy has no published RCT and uses non-standardized extracts.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
White Pineis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
White Pine Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to white pine — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of white pine allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of white pine immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of white pine extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for white pine allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing white pine extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription white pine immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat white pine allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is White Pine?
The biology, taxonomy, and clinical fingerprint of White Pine — the foundation of how SCIT targets it.
Eastern white pine (Pinus strobus) releases saccate pollen grains 60–100 μm in diameter — far larger than most aeroallergens — throughout April and June in the Northeast and Great Lakes states.
- Scientific name
- Pinus strobus
- Family
- PinaceaePine family
- Type
- Deciduous conifer tree pollen
- Native to
- Eastern North America — Maine south to Georgia, west to Great Lakes
- Allergen proteins
- No IUIS-named allergen registered for Pinus strobus; major IgE-binding bands at 42 kDa and 6–8 kDa identified by Gastaminza et al. 2009
- Particle size
- 60–100 μm (saccate, two air sacs)
- Avoidance difficulty
- Very difficult
How White Pine Allergy Presents
Symptoms by body system — useful for distinguishing White Pine sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing during April–June when pine pollen is visible outdoors
- Nasal congestion and runny nose coinciding with yellow pollen events
- Mild asthma exacerbation in confirmed pine-sensitized individuals
- Postnasal drip lasting the duration of the 6–8 week pollen season
Ocular
- Itchy, watery eyes during outdoor peak pollen periods
- Conjunctival redness after prolonged outdoor exposure
- Mild eyelid swelling in sensitized individuals
Dermal
- Contact urticaria from direct pollen contact (uncommon)
- Mild skin itching after outdoor pine pollen exposure
- Irritant dermatitis from pine resin (distinct from IgE-mediated pollen allergy)
Systemic
- Fatigue from disrupted sleep during prolonged pollen seasons
- Reduced outdoor productivity during peak April–June exposure windows
- Symptom misattribution — concurrent oak, birch, or grass often drives systemic severity
When patients show me the yellow dust on their car in May and ask for pine shots, I tell them: that visible pollen is mostly inert. The pollen actually inflaming your airways is invisible — usually oak, birch, or grass riding the same wind. Test before you commit to three years of injections.
When & Where White Pine Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through May in the Northeast and Great Lakes· Approximately 6–8 weeks of visible pollen release
US Exposure Map
12 high-intensity statesExposure intensity by state (text version)
- ME:
- High
- VT:
- High
- NH:
- High
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Moderate
- IN:
- Moderate
- OH:
- Moderate
- PA:
- High
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Moderate
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Moderate
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Moderate
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What White Pine Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
White pine shares IgE-binding proteins across the Pinus genus but does not cross-react with Cupressaceae conifers — a critical distinction for patients who confuse pine pollen with cedar fever in Texas and the Southwest.
Is SCIT Right for Your White Pine Allergy?
Answer five questions to see whether white pine allergy shots are likely to benefit your specific situation.
How severe are your spring pollen symptoms in April–June?
The White Pine SCIT Protocol
White pine SCIT follows the standard inhalant allergen build-up schedule, but uses a non-standardized extract — meaning potency is expressed in protein nitrogen units (PNU) or weight-to-volume (w/v) rather than the biological activity units (BAU) used for FDA-standardized allergens.
Your allergist will titrate the pine extract concentration upward from a very dilute starting vial, incrementally increasing dose toward the maintenance concentration. For non-standardized pine extracts, the allergist calibrates based on your skin-test reactivity to minimize the risk of large local reactions.
Once the target maintenance dose is reached, the injection schedule is individualized by your allergist. With Curex, eligible patients self-administer the ongoing maintenance dose at home, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff and a 30-minute observation after each injection. Pine extract lot-to-lot variability means your allergist may adjust the dose when vials change.
After completing a full immunotherapy course, many patients experience prolonged symptom relief. Because no RCT data exist for white pine SCIT, the decision to stop or continue is based on clinical response rather than evidence-based endpoints.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for White Pine SCIT
No published randomized controlled trial exists for white pine SCIT — the evidence base is limited to observational data, pollen-immunology studies, and extrapolation from the broader inhalant SCIT framework.
- Pinus sensitization rate (unselected)3%Bucholtz GA et al., J Allergy Clin Immunol, 1985, N=155
- SPT positivity in selected pine-allergic cohort69%Gastaminza G et al., Clin Exp Allergy, 2009, N=selected cohort
- Inhalant SCIT overall efficacy (class-level)65%Cox L et al., JACI, 2011 — AAAAI Practice Parameter meta-summary
No RCT specifically evaluates white pine SCIT. The 3.2% sensitization rate in unselected cohorts (Bucholtz 1985) suggests most patients attributing May symptoms to pine are reacting to concurrent allergens. A board-certified allergist should confirm pine-specific IgE before initiating SCIT, given the non-standardized extract and absence of trial data.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
White Pine SCIT Side Effects
White pine SCIT carries the standard side-effect profile of inhalant subcutaneous immunotherapy, with the added note that non-standardized extracts introduce lot-to-lot variability that can affect local reaction intensity when vials change.
Local reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Most common reaction; typically resolves within a few hours | Rate 30–50% | Mild |
Injection-site redness and itching More likely with first injections at each new concentration level | Rate 20–40% | Mild |
Large local reaction (>5 cm swelling) May prompt dose reduction at next visit; not predictive of systemic reaction | Rate 5–15% | Moderate |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Urticaria or generalized hives Requires epinephrine if generalized — a prescribed auto-injector is confirmed on hand; minor hives may be self-monitored during your 30-minute observation | Rate <1% | Moderate |
Rhinitis or conjunctivitis flare Temporary worsening of nasal or eye symptoms shortly after injection | Rate 1–3% | Mild |
Anaphylaxis Requires 30-minute observation after each injection; with Curex this is self-observation at home with a prescribed epinephrine auto-injector confirmed on hand and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff | Rate <0.01% per injection | Severe |
A 30-minute observation accompanies every SCIT dose. With Curex, eligible patients self-administer at home — the serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on hand, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff. No deaths from properly supervised SCIT have been reported in the US in the past decade with adherence to AAAAI safety protocols.
SCIT vs Alternatives for White Pine
For patients with confirmed pine sensitization, four main approaches exist: SCIT (the most evidence-supported immunotherapy route), sublingual immunotherapy (SLIT) drops, avoidance strategies, and daily symptom-control medications.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (no RCT; extrapolated from inhalant class) | Emerging evidence; lower evidence for pine specifically | Limited — pollen is airborne | Symptomatic relief only |
| 5-yr cost | $3,500–$15,000 | Varies by provider; not Curex's product | Low | $500–$2,000/year |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | At-home weekly self-injection (build-up) | Daily drops at home | HEPA filters, window closing in season | Daily pills/sprays |
| Safety | USP <797> serum; Virtual Shot Room–supervised dosing; 30-min self-observation | Lower systemic risk vs SCIT | Safe | Safe; antihistamine sedation risk |
| Lasting effect | Possible long-term tolerance | Possible lasting benefit | No immune modification | No lasting effect |
SCITBest
SLIT
Avoidance
Medications
For patients with confirmed pine sensitization, Curex now delivers disease-modifying SCIT at home with pricing confirmed in a current program quote — replacing the roughly 156 in-office injections of a traditional three-year course with at-home self-injection. The serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff, and a prescribed epinephrine auto-injector is confirmed on hand under board-certified allergist oversight.
What White Pine SCIT Actually Costs
Most major insurers cover inhalant SCIT under standard allergy benefits when ordered by a board-certified allergist and medically necessary sensitization is confirmed. Because pine extract is non-standardized, coverage decisions can vary by plan; verify prior authorization requirements with your insurer before starting. Curex at-home IgE testing identifies specific white pine sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your white pine allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
White Pine SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Yes — the highly visible yellow pollen rain in the Northeast and Great Lakes in May is primarily white pine (Pinus strobus). However, visibility does not equal allergenicity. White pine pollen grains are 60–100 μm with two large air sacs, making them significantly larger than most aeroallergens. Bucholtz et al. (J Allergy Clin Immunol, 1985) found only 3.2% of pollen-sensitive patients tested positive to Pinus in an unselected cohort. The invisible pollens — oak, birch, grass — released at the same time are typically the actual immune drivers. An allergist can determine via skin or blood testing whether your IgE is directed at pine or at something else blooming simultaneously.
There is no published randomized controlled trial for white pine (Pinus strobus) SCIT specifically, which is an important evidence gap. The general inhalant SCIT framework suggests benefit for confirmed sensitization, and Gastaminza et al. (Clin Exp Allergy, 2009) confirmed IgE-binding proteins at 42 kDa and 6–8 kDa in selected pine-allergic patients, establishing a biologic rationale. However, without RCT data, efficacy cannot be quantified for pine the way it can for, say, ragweed (85% symptom reduction, Creticos 2006 NEJM) or cat (70%, Alvarez-Cuesta 2007). Your allergist should weigh this uncertainty when discussing SCIT candidacy.
White pine and cedar fever (mountain cedar, Juniperus ashei) are caused by completely different pollen proteins with no cross-reactivity. White pine is Pinaceae; mountain cedar is Cupressaceae — a different botanical family. Pine's allergenic proteins are in the 42 kDa and 6–8 kDa range; cedar's major allergen is Jun a 1, a pectate lyase. Pine does not cross-react with any Cupressaceae species (Gastaminza 2009). This distinction matters for Southwest patients: a Texan with winter cedar fever symptoms is not going to benefit from pine SCIT, and vice versa. Testing clarifies which family — or both — is responsible.
Yes — antihistamines can be continued during white pine SCIT and are often encouraged during the build-up phase to reduce local injection-site reactions. Some allergists recommend taking an antihistamine 30–60 minutes before each injection visit. Long-term daily antihistamine use does not interfere with the immunologic mechanism of SCIT, which works through T-cell tolerance and IgG4 class-switching rather than H1 receptor blockade. Discuss timing and dose with your prescribing allergist, as protocols vary.
Missed injections require a dose adjustment upon return, depending on how long you were away from the schedule. Most AAAAI-compliant protocols recommend stepping back by one concentration vial for gaps of 2–6 weeks and restarting the build-up sequence for gaps longer than 8 weeks. The exact protocol depends on your allergist's clinical judgment and the non-standardized extract's specific lot characteristics. Because pine extract potency can vary between lots, your allergist may also adjust your return dose if a new vial lot is being used. Always notify your care team before your next dose if you have missed visits.
Most major health insurers cover inhalant subcutaneous immunotherapy under standard allergy benefits when ordered by a board-certified allergist and supported by documented sensitization. Because pine extract is non-standardized (no FDA-assigned BAU potency), some insurers require prior authorization and may request evidence of clinically relevant sensitization confirmed by skin prick test or specific IgE blood testing. Coverage for extract preparation (CPT 95165) varies by plan. Contact your insurance company before starting SCIT to understand cost-sharing obligations, and confirm your allergist participates in your network.
The only reliable way to distinguish white pine from oak sensitization is a specific IgE panel ordered by a board-certified allergist. Skin prick testing or a serum-based IgE blood test (ImmunoCAP or similar) measures reactivity to each allergen separately. Oak and white pine pollen seasons overlap significantly in the Northeast — both peak in April through May — making clinical timing alone unreliable. If testing shows oak or birch IgE is significantly higher than pine IgE, directing immunotherapy at oak or birch is likely more cost-effective. An allergist can review a multi-tree panel and help you prioritize the SCIT target based on which allergens have the strongest documented clinical relevance.
Children can receive subcutaneous immunotherapy for inhalant allergens including pine, provided they meet standard candidacy criteria: confirmed sensitization, inadequate medication control, and appropriate age (most allergists begin SCIT no earlier than age 5–6 in a clinical setting). For white pine specifically, the same evidence limitations apply to pediatric patients as to adults — no RCT data and non-standardized extract. Note that Curex's at-home pilot is currently open to patients age 12 and older; children under 12 should receive SCIT through an in-clinic pediatric allergist. For eligible older patients, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) recorded a systemic reaction rate of just 0.16% per patient across 23,614 patients and 2,021,600 injections, with no fatalities — lower than the 3%–14% typically seen with office-based shots. A pediatric allergist or board-certified allergist with pediatric experience should evaluate the child's full allergen sensitization profile before prescribing pine SCIT, to ensure that the correct allergen target is identified and that the clinical benefit justifies the injection schedule commitment.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.